William Wierda, MD, PhD, is a qualified professor and a medical director at MD Anderson Cancer Center. He is also head of the chronic lymphocytic leukemia (CLL) section in the Department of Leukemia, where he directs clinical and translational efforts in CLL and low-grade lymphoproliferative diseases.
Dr. Wierda earned his PhD in 1992 and MD in 1993 from the University of Health Sciences at Chicago Medical School. He also completed a fellowship in Hematology/Oncology at University of California in San Diego, where he trained under the mentorship of Dr. Thomas Kipps. Dr. Wierda moved to Houston as an Assistant Professor of Medicine in the Department of Leukemia at MDACC in 2001, and since, was promoted to Associate Professor of Medicine in 2007. Dr. Wierda continued clinical and translational research in CLL and became Professor of Medicine in 2012. Dr. Wierda’s outpatient clinical activities are dedicated to seeing and treating patients with CLL. At MDACC, Dr. Wierda has been Principal Investigator (PI), Co-PI, or collaborator in many clinical trials, conducting translational research in CLL. Dr. Wierda has directed clinical research efforts in CLL at various institutions, including, Mayo Clinic, The Ohio State University, UCSD, Dana Farber Cancer Institute, Long Island Jewish Hospital, as well as MD Anderson Cancer Center. He has published numerous peer-reviewed articles on clinical and translational research in CLL and drug development and has given many lectures at national and international scientific meetings.
Dr. Wierda’s particular research interests in CLL are prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.